Analgesics. Opioids and related analgesics
Conditions
Interventions
Intervention 1: Intervention group: Methoxyflurane, a fluorinated hydrocarbon inhalation agent available in 3 cc ampoules, used in the Pentorax inhaler (manufactured by MDI, Melbourne, Australia). Thr
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: Patients with upper or lower fracture Age between 20 to 55 Informed consent to participation in the study
Exclusion criteria
Exclusion criteria: Impaired level of consciousness (Glasgow coma score less than 15) Hemodynamic disturbance during use (systolic blood pressure less than 90 mmHg, peripheral rate less than 60 beats per minute, breathing rate less than 8 per minute, blood oxygen saturation less than 90% Use of substances, alcohol, sedatives or pain relievers in the past 48 hours History of taking Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Serotonin Receptors Reuptake Inhibitors, Phenothiazines, and sleeping pills Suffering from chronic diseases such as congenital or acquired heart diseases, chronic liver failure, bile duct diseases, kidney failure and chronic lung disease according to history and clinical examination. Allergy to Morphine or Penthrox Weight more than 100 kg Lack of informed consent Patient non-cooperation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain number in the Visual Analogue Scale (VAS). Timepoint: 10, 20, 30, 60 minutes after receiving the medicine. Method of measurement: The Visual Analogue Scale (VAS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Gulban
Esfahan University of Medical Sciences
Outcome results
None listed